Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : International Nursing Services Inc, old (NURS) new (MDIX) -- Ignore unavailable to you. Want to Upgrade?

To: Chris O'Keefe who wrote (1332)	5/23/1998 1:08:00 PM
From: Double Dipper	Respond to of 2911

Chris, As a lurker, non shareholder, your take is very much in line with my own. I have read much speculation on this thread over the last few weeks concerning takeovers, poison pills and special board meetings. Nothing yet from the company regarding contracts, potential contracts or new information that would stave of the impending delisting. Despite this, the proposed Cymedix internet potential is interesting enough to keep me watching. I would also appreciate hearing more from those who have been in the stock for awhile. Why they got in, what has changed and given today's business outlook, what keeps them in and would they do it again if they were looking over the fence thinking about it. Kevin

To: Chris O'Keefe who wrote (1332)	5/23/1998 3:06:00 PM
From: Mike Moran	Read Replies (2) \| Respond to of 2911

Chris, you are one smart dude. Great post. You only left out one small piece. MDIX has recently created a few waves that lapped up against other industries. One such industry, computer services and general computer business consulting, has taken notice. This industry is dominated by two large players, Computer Associates and Computer Sciences, plus IBM, AT&T and others. Both CA and CSC each just spent big bucks to buy large healthcare consulting arms, and are both on quiet quests to buy their way into the medical information field. One of these two companies is in almost constant contact with MDIX. What's easier to do. Buy a company for chicken feed by paying a premium over $.375 per share or having to study a market entry situation and then paying $1.25 per share?

To: Chris O'Keefe who wrote (1332)	5/23/1998 4:02:00 PM
From: Doug Fir	Read Replies (2) \| Respond to of 2911

Chris, some people this board seem to forget good news, and search out the bad. You'd think it would be the opposite. In fact, MDIX already has 2 contracts. We will see the revenue in the 2nd quarter, although they may be discounted by up to 30% due to introductory discounts. From the 8-k: To date, we have completed two commercial sales of the Cymedix Lynx product. The first represents a three-year contract with Loyola University Medical Center of Chicago, which will be networked to at least 200 physicians with the medical center's laboratory services outreach program. Affiliate hospitals of Loyola are expected to be added in the future, thereby increasing the potential number of physicians utilizing Cymedix Lynx throughout the Chicago area to more than 1,000. The second contract is a multi-year licensing agreement with Medical Technology Corporation (MTC), a division of MTC Laboratory, Inc. of Miami. Under the terms of the agreement, Cymedix Lynx will be offered to a minimum of 200 physician offices affiliated with MTC throughout Southern Florida. I don't mind naysayers, because they contribute important checks and balances to the longs enthusiasm. It helps keep the facts in check, but sheeesh! This stuff has been posted before, and is in the financials. Hey people, remember those? They're the big white envelopes you have to throw out every three months. Forgive my ranting :)! Hope this helped clear up some of your questions. Good luck. Doug